Feedback / Questions
zipalertinib (CLN-081) - Cullinan Therap, Otsuka
Zipalertinib: Launch for 2L NSCLC in 2026
(Otsuka)
-
Aug 1, 2025 -
Q2 FY2025 Results: Regulatory filing for 1L NSCLC in 2027
Filing
•
Lung Cancer • Non Small Cell Lung Cancer • Oncology
https://ssl4.eir-parts.net/doc/4578/ir_material_for_fiscal_ym3/183426/00.pdf
Aug 1, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious